Australian Technology Park, National Innovation
Centre, 4 Cornwallis Street
New South Wales
Tel: 612 9209 4020
NeuClone is a biotechnology company developing and commercialising high quality biosimilars. The company is focused on creating a deep pipeline of clinically identical biosimilars at significantly reduced prices for entry into both new and established markets.
Founder and CEO: Noelle Sunstrom
10 articles about NeuClone
NeuClone Announces Positive Results from Phase I Study of Stelara® (ustekinumab) Biosimilar Candidate
NeuClone Pharmaceuticals Ltd (NeuClone) today announced its biosimilar candidate of Stelara ® (ustekinumab), NeuLara, has successfully met all primary and secondary endpoints in a Phase I clinical trial. This includes all pre-specified criteria demonstrating the clinical pharmacokinetic (PK) similarity of NeuLara, compared to US-
NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company developing high-quality biosimilar products, today disclosed two additional biosimilars in active development. The products are biosimilar candidates referencing Opdivo ® (nivolumab) and Keytruda ® (pembrolizumab). These biosimilars reference two antibody products that bl
4/16/2020Global pharma and life sciences companies provide updates on their business operations and pipelines.
NeuClone Announces Completion of Subject Visits in Stelara® (ustekinumab) Biosimilar Phase I Clinical Trial
NeuClone Pharmaceuticals Ltd announced successful completion of monitoring visits and blood sampling for subjects in the Phase I clinical trial for its Stelara® biosimilar candidate, NeuLara.
NeuClone Announces First Human Dose of Stelara® (Ustekinumab) Biosimilar Candidate in Phase I Clinical Trial
NeuClone, a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced it has commenced dosing of Stelara® (ustekinumab) biosimilar candidate, NeuLara, in a Phase I clinical trial.
5/16/2019Pharma and biotech companies from across the globe provide business and pipeline updates, with news from Gecko, ValGenesis, NeuClone, Zymeworks, and more.
NeuClone to Initiate Phase I Clinical Trial of Stelara (Ustekinumab) Biosimilar, the Second Biosimilar from the 10-product Portfolio with Serum Institute
NeuClone Pharmaceuticals Ltd. announced it will initiate the Phase I clinical trial of its Stelara® biosimilar in the second half of 2019.
NeuClone Announces its Sixth Biosimilar Candidate Perjeta(R) (Pertuzumab) for use in Combination Therapy with Herceptin(R) (Trastuzumab)
The product is a biosimilar candidate of Perjeta® (pertuzumab) currently in preclinical development.
NeuClone Announces First Human Dose of Herceptin® (trastuzumab) Biosimilar Candidate in Phase I Clinical Trial
NeuClone Ltd, a biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced it has commenced first-in-human dosing of its Herceptin® (trastuzumab) biosimilar candidate, in a Phase I clinical trial.
NeuClone Discloses Details of its Fifth Product: a Biosimilar Candidate for Prolia/XGEVA (Denosumab)
NeuClone Pty. Ltd. today disclosed the fifth biosimilar candidate being developed in its pipeline of mAb products.